West Pharmaceutical Services is trading at $420.96, up 5.41%, after strong Q3 results and raised 2026 guidance. - On October 29, the company reported Q3 sales of $874.5 million, up 8.7%, and adjusted EPS of $2.66, beating analyst estimates. - Management raised 2026 net sales guidance to $3.41–$3.42 billion and adjusted EPS guidance to $9.38–$9.48. - Market indices were lower, so broad market sentiment does not explain the gain.